文献速递前列腺癌

真实世界中阿帕他胺治疗的转移性激素敏感性前列腺癌患者的前列腺特异性抗原最低值与肿瘤控制结局:单中心分析

Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis.
PubMed 文献 · Eur Urol Oncol · 2024-08-31

本研究基于单中心机构前列腺癌数据库,纳入107例接受阿帕他胺治疗的转移性激素敏感性前列腺癌(mHSPC)患者,验证前列腺特异性抗原(PSA)最低值截断值(SWOG试验<0.2 ng/ml;TITAN试验超低值≤0.02 vs 0.02-0.2 vs >0.2 ng/ml)及PSA反应≥99%与至去势抵抗性前列腺癌时间(ttCRPC)和总生存(OS)的关系,并与阿比特龙治疗患者比较。结果显示达到超低PSA最低值≤0.02 ng/ml者比例最高(40.2%),且与更长的ttCRPC和OS相关(均p<0.05);阿帕他胺组达到超低PSA最低值≤0.02 ng/ml的比例显著高于阿比特龙组(40.2% vs 8.8%),ttCRPC显著更长(37个月 vs 22个月,p=0.001)。

要点

  • 107例阿帕他胺治疗的mHSPC患者中,40.2%达到超低PSA最低值≤0.02 ng/ml。
  • 达到SWOG定义PSA最低值<0.2 ng/ml或超低值≤0.02 ng/ml者,至mCRPC时间和OS均更长(均p<0.05)。
  • 阿帕他胺组超低PSA最低值≤0.02 ng/ml比例高于阿比特龙组(40.2% vs 8.8%),ttCRPC更长(37个月 vs 22个月,p=0.001)。

核心结论

  • 在真实世界中,大多数接受阿帕他胺治疗的mHSPC患者达到超低PSA最低值,且与更好的肿瘤控制结局相关。
  • PSA反应≥99%预测更好的结局。
  • 头对头比较中,阿帕他胺相比阿比特龙获得更好的PSA动力学和ttCRPC结局。

研究设计与样本

  • 基于机构前列腺癌数据库的单中心分析,纳入107例接受阿帕他胺治疗的mHSPC患者,中位年龄68岁,基线PSA 29 ng/ml。
  • 检验现有PSA最低值截断值(SWOG试验:<0.2 ng/ml;TITAN试验超低值:≤0.02 vs 0.02-0.2 vs >0.2 ng/ml)及PSA反应(≥99%)与ttCRPC和OS的关系,并与阿比特龙治疗的mHSPC患者比较。

主要发现

  • 40.2%的患者达到超低PSA最低值≤0.02 ng/ml,为最高比例组。
  • 达到SWOG 9346定义PSA最低值<0.2 ng/ml和超低PSA最低值≤0.02 ng/ml的患者,至mCRPC时间和OS最长(均p<0.05)。
  • 80%的阿帕他胺治疗患者达到PSA反应≥99%,这些患者至mCRPC时间和OS结局均优于PSA反应<99%者(均p<0.05)。
  • 阿帕他胺组达到超低PSA最低值≤0.02 ng/ml的比例显著高于阿比特龙组(40.2% vs 8.8%),ttCRPC显著更长(37个月 vs 22个月,p=0.001),多变量调整后及仅高危mHSPC患者的敏感性分析中仍显著。

关键数值与推荐

  • PSA最低值截断值:SWOG试验<0.2 ng/ml;TITAN试验超低值≤0.02 vs 0.02-0.2 vs >0.2 ng/ml。
  • PSA反应阈值:≥99%。
  • 阿帕他胺组超低PSA最低值≤0.02 ng/ml比例为40.2%,阿比特龙组为8.8%。
  • 阿帕他胺组ttCRPC为37个月,阿比特龙组为22个月(p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究受回顾性设计限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Currently available post hoc phase 3 trial-derived data suggest better cancer-control outcomes in apalutamide-treated metastatic hormone-sensitive prostate cancer (mHSPC) patients achieving an (ultra)low prostate-specific antigen (PSA) nadir. This study aims to validate ultralow PSA nadir cutoffs. METHODS: Relying on an institutional prostate cancer database, 107 eligible patients were yielded. The currently available PSA nadir cutoffs (SWOG trial: <0.2 ng/ml; ultralow TITAN trial: ≤0.02 vs 0.02-0.2 vs >0.2 ng/ml) and PSA responses (≥99%) were tested for time to castration-resistant prostate cancer (ttCRPC) and overall survival (OS) in mHSPC patients treated with apalutamide. Finally, comparisons were made against abiraterone mHSPC treatment. KEY FINDINGS AND LIMITATIONS: Overall, 107 mHSPC patients treated with apalutamide at a median age of 68 yr and baseline PSA of 29 ng/ml were included. The highest proportion of included patients (40.2%) achieved an ultralow PSA nadir of ≤0.02 ng/ml. Patients reaching the SWOG 9346-defined PSA nadir of <0.2 ng/ml and ultralow PSA nadir of ≤0.02 ng/ml harbored the longest time to metastatic castration-resistant prostate cancer (mCRPC) and OS (all p < 0.05). Moreover, 80% of mHSPC patients treated with apalutamide achieved a PSA response of ≥99%. These patients also harbored better time to mCRPC and OS outcomes, relative to patients with a <99% PSA response (both p < 0.05). In the second step of analyses, a comparison against abiraterone patients showed a significantly higher rate of achieving an ultralow PSA nadir of ≤0.02 ng/ml: 40.2% versus 8.8% for apalutamide versus abiraterone, resulting in a significantly longer ttCRPC for the apalutamide-treated (37 mo) than for the abiraterone-treated (22 mo) group (p = 0.001), even after multivariable adjustment and in sensitivity analyses for high-risk mHSPC patients only. The study is limited by its retrospective design. CONCLUSIONS AND CLINICAL IMPLICATIONS: In the real-world setting, most mHSPC patients treated with apalutamide achieve an ultralow PSA nadir, which is associated with better cancer-control outcomes. Moreover, a PSA response of ≥99% predicts better outcomes. In head-to-head comparisons, apalutamide achieves better PSA kinetics and ttCRPC outcomes than abiraterone. PATIENT SUMMARY: A prostate-specific antigen (PSA) nadir of <0.02 ng/ml and PSA responses ≥99% are associated with better cancer-control outcomes in metastatic hormone-sensitive prostate cancer patients treated with apalutamide.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wenzel M, Cano Garcia C, Humke C, et al. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis. Eur Urol Oncol. 2024. PMID: 39218743. doi:10.1016/j.euo.2024.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。